Rash rates with egfr inhibitors: meta-analysis

Por Mittmann, N., Seung, S.J.
Publicado em 2011

Importance of cost estimates and cost studies

Por Mittmann, N., de Oliveira, C.
Publicado no Curr Oncol (2016)

Cost effectiveness of tac versus fac in adjuvant treatment of node-positive breast cancer

Por Mittmann, N., Verma, S., Koo, M., Alloul, K., Trudeau, M.
Publicado em 2010

Meta-analysis and adverse drug reactions

Por Mittmann, N, Liu, B A, Knowles, S R, Shear, N H
Publicado em 1999

Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotonin reuptake inhibitors: a review of spontaneous reports...

Por Liu, B A, Mittmann, N, Knowles, S R, Shear, N H
Publicado em 1996

The use of granulocyte colony–stimulating factors in a Canadian outpatient setting

Por Fine, S., Koo, M., Gill, T., Marin, M., Poulin–Costello, M., Barron, R., Mittmann, N.
Publicado em 2014

Radiation costing methods: a systematic review

Por Rahman, F., Seung, S.J., Cheng, S.Y., Saherawala, H., Earle, C.C., Mittmann, N.
Publicado no Curr Oncol (2016)

Examining the medical resource utilization and costs of relapsed and refractory chronic lymphocytic leukemia in Ontario

Por Hassan, S., Seung, S.J., Cheung, M.C., Fraser, G., Kuriakose, B., Trambitas, C., Mittmann, N.
Publicado no Curr Oncol (2017)

Resource utilization and costs of managing patients with advanced melanoma: a Canadian population-based study

Por Gwadry-Sridhar, F., Nikan, S., Hamou, A., Seung, S.J., Petrella, T., Joshua, A.M., Ernst, S., Mittmann, N.
Publicado no Curr Oncol (2017)

Impact of country-specific EQ-5D-3L tariffs on the economic value of systemic therapies used in the treatment of metastatic pancreatic cancer

Por Lien, K., Tam, V.C., Ko, Y.J., Mittmann, N., Cheung, M.C., Chan, K.K.W.
Publicado no Curr Oncol (2015)

A Canadian economic analysis of U.S. Oncology Adjuvant Trial 9735

Por Bernard, L.M., Verma, S., Thompson, M.F., Chan, B.C.F., Mittmann, N., Asma, L., Jones, S.E.
Publicado em 2011

Cost-effectiveness of systemic therapies for metastatic pancreatic cancer

Por Tam, V.C., Ko, Y.J., Mittmann, N., Cheung, M.C., Kumar, K., Hassan, S., Chan, K.K.W.
Publicado em 2013

Estimation of drug cost avoidance and pathology cost avoidance through participation in NCIC Clinical Trials Group phase III clinical trials in Canada

Por Tang, P.A., Hay, A.E., O’Callaghan, C.J., Mittmann, N., Chambers, C.R., Pater, J.L., Leighl, N.B.
Publicado no Curr Oncol (2016)

Population-based utilization of radiation therapy by a Canadian breast cancer cohort

Por Mittmann, N., Seung, S.J., Liu, N., Porter, J., Saskin, R., Hoch, J.S., Evans, W.K., Leighl, N.B., Trudeau, M., Earle, C.C.
Publicado em 2014

Predictors of adjuvant treatment for pancreatic adenocarcinoma at the population level

Por Kagedan, D.J., Dixon, M.E., Raju, R.S., Li, Q., Elmi, M., Shin, E., Liu, N., El-Sedfy, A., Paszat, L., Kiss, A., Earle, C.C., Mittmann, N., Coburn, N.G.
Publicado no Curr Oncol (2016)

Population-based home care services in breast cancer: utilization and costs

Por Mittmann, N., Isogai, P.K., Saskin, R., Liu, N., Porter, J.M., Cheung, M.C., Leighl, N.B., Hoch, J.S., Trudeau, M.E., Evans, W.K., Dainty, K.N., Earle, C.C.
Publicado em 2012

Health system costs for stage-specific breast cancer: a population-based approach

Por Mittmann, N., Porter, J.M., Rangrej, J., Seung, S.J., Liu, N., Saskin, R., Cheung, M.C., Leighl, N.B., Hoch, J.S., Trudeau, M., Evans, W.K., Dainty, K.N., DeAngelis, C., Earle, C.C.
Publicado no Curr Oncol (2014)

A population-based study of the epidemiology of pancreatic cancer: a brief report

Por Raju, R.S., Coburn, N., Liu, N., Porter, J.M., Seung, S.J., Cheung, M.C., Goyert, N., Leighl, N.B., Hoch, J.S., Trudeau, M.E., Evans, W.K., Dainty, K.N., Earle, C.C., Mittmann, N.
Publicado no Curr Oncol (2015)